Long term outcomes of idasanutlin therapy in hydroxyurea-refractory polycythemia vera patients
Idasanutlin is a small molecule inhibitor that restores p53 activity, triggering apoptosis. Two trials (phase 1/2) of idasanutlin therapy in polycythemia vera patients that were intolerant or refractory to hydroxyurea resulted in substantial clinical and molecular responses. Here the long term outcomes of these patients are reported.
Authors
- R Hoffman
- Megan Metzger (ORCID: https://orcid.org/0009-0005-6718-2974)
- Jayanshu Jain
- Abdulraheem Yacoub (ORCID: https://orcid.org/0000-0001-5293-4620)
- Margherita Maffioli (ORCID: https://orcid.org/0000-0002-2268-391X)
- Grace Van Hyfte (ORCID: https://orcid.org/0009-0001-8791-2285)
- Natalia Rosas
- John O. Mascarenhas (ORCID: https://orcid.org/0000-0002-8400-0483)
- Julian A. Waksal
- Aaron Gerds
- Vikas Gupta (ORCID: https://orcid.org/0000-0002-1419-8607)
- Francesco Passamonti
Institutions
- Cleveland Clinic (US)
- University Health Network (CA)
- University of Milan (IT)
- Cancer Institute (WIA) (IN)
- Princess Margaret Cancer Centre (CA)
- The Ohio State University Wexner Medical Center (US)
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- Tisch Hospital (US)
- Azienda Socio Sanitaria Territoriale Lariana (IT)
- University of Kansas Medical Center (US)
- Tisch Cancer Institute
- New York University (US)
Publication Details
- Journal
- Leukemia & lymphoma/Leukemia and lymphoma
- Published
- 2026-05-18
- DOI
- https://doi.org/10.1080/10428194.2026.2666850
- Primary Topic
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00